SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001640334-21-001859
Filing Date
2021-08-13
Accepted
2021-08-13 13:32:10
Documents
44
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 6-K nymox_6k.htm   iXBRL 6-K 42127
2 QUARTERLY REPORT FOR THE QUARTER ENDED JUNE 30, 2021 nymox_ex991.htm   iXBRL EX-99.1 406773
3 CEO CERTIFICATIONS nymox_ex992.htm EX-99.2 12335
4 CEO CERTIFICATIONS nymox_ex993.htm EX-99.3 12265
  Complete submission text file 0001640334-21-001859.txt   2129831

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA nymox-20210630.xsd EX-101.SCH 35934
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE nymox-20210630_lab.xml EX-101.LAB 136867
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE nymox-20210630_cal.xml EX-101.CAL 30861
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nymox-20210630_pre.xml EX-101.PRE 110504
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nymox-20210630_def.xml EX-101.DEF 48630
10 EXTRACTED XBRL INSTANCE DOCUMENT nymox_6k_htm.xml XML 357226
Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2
Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669
NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-12033 | Film No.: 211171219
SIC: 2835 In Vitro & In Vivo Diagnostic Substances